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Background and Aims:This study aimed to assess the association between the low 
maternal serum of pregnancy-associated plasma protein-A (PAPP-A) during the first 
trimester and pregnancy outcomes.
Materials and Methods: We conducted a prospective cohort study of 118 pregnant 
women undergoing first-trimester screening between 2016 and 2017 at Taleghani and 
Imam Hussein hospital in Tehran, Iran. We recorded demographic data, and blood 
samples were taken to analyze the value of PAPP-A, based on which we divided the 
participants into two groups: PAPP-A >10th percentile as a control group, and PAPP-A 
≤10th percentile as a study group. The pregnancies underwent follow-up observa-
tions for obstetric complications during pregnancy. Chi-square or Fisher exact test and 
Mann-Whitney U test were applied to analyze data by SPSS 26.
Results: In this study, 118 pregnant women were enrolled. Our results show a sig-
nificant association between low PAPP-A (<10th percentile) and preterm labor, small 
for gestational age (SGA), hypertension, preeclampsia (P < 0.05), but no statistically 
significant difference was found between low PAPP-A and stillbirth. Demographic data, 
including age, gravida, parity, BMI, had no relationship with low PAPP-A, significantly 
(P > 0.05).
Conclusion: Low PAPP-A is associated with adverse outcomes; thus, measuring the 
PAPP-A within the first trimester is suggested for timely management.
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UppPregnancy complications are the consequence of risk 
factors; however, most of the adverse effects occur in wom-
en with no related risk factors [1]. Placenta as a barrier and 
nutritional transporter plays a major role in associated ad-
verse outcomes of pregnancy, such as small for gestational 
age or preterm delivery in a fetus, developing hypertension 
or preeclampsia in pregnant women. Consequently, the im-
paired placental function owing to the failure of trophoblast 
invasion causes ischemia and fetus hypoxia, which predis-
pose the pregnant women and their fetus to the following 
sequela. The syncytiotrophoblast secret PAPP-A, and the 
low level of PAPP-A would be detected in the placenta 
insufficiency. PAPP-A is a protease targeted insulin-like 
growth factor binding protein-4 (IGFBP-4), and a lower 
level of PAPP-A affects insulin-like growth factor (IGF) 
level. IGF stimulates the placenta and fetus development; 
thus, the lower level of IGF leads to restricted intrauter-
ine growth and associated pregnancy complications such as 
preterm labor and preeclampsia [2-7].
The biomarkers reflect the fetus and maternal status in 
screening tests. ß-HCG, pregnancy-associated plasma pro-
tein-A(PAPP-A), progesterone, activin A, Inhibin A, ar-
tery pulsatility index, and the maternal serum of placental 
growth factor are the predictors [2, 8]. No single predictor 
is accurate to measure the risk of possible adverse effects 
[6], and recent studies suggest the combination screening 
study [9]. Assessment of the biomarkers and the maternal 
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ered as gestational age < 37 weeks. WHO defines stillbirth, 
a fetus is born dead ≥ 28 weeks’ gestation. We used IBM 
SPSS statistics 26 for statistical analysis. Chi-square and 
Fisher exact test for categorical variables and Mann-Whit-
ney U test for continuous non-distributed variables were 
applied to compare pregnancy complications. P-value 
≤0.05 was considered statistically significant.R
RESULTS
In this study, 118 women in the first trimester were enrolled. 
In 59 of the participants, low PAPP-A MoM was detected. 
Demographic data are demonstrated in table 1.
The mean BMI of pregnancies were 29.8±26.24. In the 
study group, 38 cases of the study group and 38 women 
of the control group had BMI>25. The age of participants 
ranged from 21 to 34, with 27.51±3.78 as the average; 22 
women of the study group and 23 women of the control 
group were ≥30 years. BMI, gravida, parity, and age were 
statistically similar in both groups; however, BMI, age, 
gravity, and parity were higher in the low PAPP-A group.
Seven out of eight cases with SGA were in the study group 
and showed a statistically significant (P-value < 0.05). 
The correlation between SGA and demographic data was 
surveyed, but the results indicated an insignificant preva-
lence. Low PAPP-A group constituted a higher prevalence 
of preterm delivery, 6.77% of 8.47% cases, and showed a 
significant difference compared to the control group (P-val-
ue < 0.05). Table 2 outlines more prevalence of pregnan-
cy hypertension (15.25% versus 3.38%) and preeclampsia 
(11.86% versus 1.69%) in the low PAPP-A MoM group. 
Significant differences in pregnancy hypertension (P = 
0.02) and preeclampsia (P = 0.02) were observed between 
the two groups. All stillbirths with the low frequencies of 2 
cases were in the low PAPP-A MoM group, but no signifi-
cant differences were detected between the two groups (P = 
0.15). No association was found between stillbirth and age 
or BMI of pregnant women. 
DISCUSSION
The study considers the low PAPP-A (<10th percentile) as 
a predictor of preterm labor, SGA, preeclampsia, and preg-
nancy hypertension based on the results, but none of the 
demographic factors such as BMI, age, parity, and gravida 
had a significant relation with the PAPP-A. 
factors affecting them provide a diagnostical approach to 
manage the pregnancies. 
PAPP-A, in part of the first-trimester screening test for 
Down’s syndrome, provides an available predictor of ma-
ternal status [9]. Current studies support the association 
between the PAPP-A and increased risk of preeclampsia, 
SGA, preterm labor, and stillbirth [10, 11]. This study aims 
to investigate the association between low PAPP-A and 
pregnancy complications in low-risk women for SGA, still-
birth, preeclampsia, and preterm labor, and to figure out the 
relationship between the low PAPP-A and maternal factors 
in Iran.
MATERIALS and METHODS
We conducted a prospective cohort observational study of 
118 pregnancies in the first trimester referred to Taleghani 
and Imam Hussein hospital between 2016 and 2017 for pre-
natal care. Informed consent was obtained from the partic-
ipants, and The Research Committee of Shahid Beheshti 
University issued Codes of ethics for the study (IR.SBMU.
MSP.REC.1397.42). All singleton pregnancies undergoing 
first-trimester screening tests were included, and the exclu-
sion criteria were twin pregnancies, history of congenital 
abnormal parturition, and inaccessibility to the participants 
or incomplete follow-up. Demographic data, including age, 
gravida, parity, and BMI prospectively, were recorded at 
the time of blood sampling. Samples of 5 ml venous blood 
were transferred to the laboratory certified by the Ministry 
of Treatment and Medical Education of Iran. The concen-
tration of PAPP-A was adjusted for gestational age, ma-
ternal weight, ethnicity, smoking, number of fetuses, and 
method of conception, which was expressed in multiples of 
the median (MoM). The recruited pregnancies were divided 
into two groups: a) low PAPP-A defined as <10th percentile 
as a study group and b) normal PAPP-A defined as ≥10th 
percentile (equivalent to 0.53 MoM) as a control group. The 
outcomes were the rate of SGA, preterm delivery, stillbirth, 
hypertension, and preeclampsia that were assessed in both 
groups. According to International guidelines, preeclamp-
sia referred to hypertension (≥140/90 mmHg twice 6-hour 
apart) and proteinuria (≥300mg/day on 24-hour urine out-
put or ≥+1 in dipstick on a midstream urine sample at least 
twice 24-hour apart), SGA referred to bodyweight <10th 
percentile for gestational age and preterm delivery consid-
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Table 1. Demographic data
Variable Number Value
The mean BMI † 26.24±2.06 
Mean Age ‡ 27.51±3.78 








† (kg/m2±SD); ‡ (year±SD); § n(%)
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In our study, no correlation was found between low PAPP-A 
and stillbirth which confirm the results of other studies 
[12]. A large scale prospective surveys on 33395 women 
by L.Dugoff et al. (FASTER trial) reported that the PAPP-
A≤5th percentile has a significant association with sponta-
neous fetal loss at ≤24 weeks of gestation and intrauterine 
fetal death >24 weeks of gestation [13].
PAPP-A is considered as a predictor for gestational hyper-
tension in common with other studies [14] and E.Antwi et 
al. suggested adding PAPP-A and PIGF to the clinical algo-
rithm [15]. In our study, we observed a significant relation 
between preeclampsia (PE), pregnancy hypertension, and 
low PAPP-A  in the agreement of other studies [16], but not 
in several studies [17] possibly for a low incidence of PE. 
Since the high BMI as confounding factor can contribute to 
developing preeclampsia, we excluded women’s BMI ≥30 
in our study. Luewan et al. enrolled 3663 women; 357 cas-
es with low PAPP-A (<10th percentile) and 3306 women 
with normal PAPP-A, which found an increased risk of pre-
eclampsia in association with the low PAPP-A [18]. Poon 
et al. reported a bigger fall of PAPP-A level in develop-
ing early preeclampsia [19]. M.Honarjoo et al. stated that 
the low PAPP-A (<4 MoM) shows a 2.05-fold increase in 
developing preeclampsia based on the evaluation of 4605 
pregnant Iranian women [20].
Low PAPP-A association with SGA is well established [16]. 
M.Hoseini et al. evaluated 715 pregnant women in Imam 
Hussein hospital and concluded that the best cutoff PAPP-A 
value to predict SGA in the Iranian population is 0.75 MoM 
with high sensitivity and specificity [21]. In another study 
by Cowen and Spencer, it was found that the severity of 
SGA has a linear relation with a decrease in PAPP-A [22], 
and the sensitivity of the PAPP-A test increases with rising 
the severity of SGA [23].
Our results show the association between preterm labor 
and low PAPP-A, which is consistent with previous studies 
[24]. FASER trial indicated that similar to SGA, increas-
ing the sensitivity is accompanied by increasing the se-
verity of preterm labor; however, the studies considered the 
PAPP-A as a poor biomarker for determination of SGA and 
the preterm labor [13, 23]. Consistent with the findings; a 
meta-analysis of 32 studies assessed 175240 pregnant wom-
en, which reported 67.4% sensitivity and 67.5% specificity 
for PAPP-A ≤0.745 MoM [25].
Although some studies have suggested adding the other 
screening tests such as biophysical markers would be more 
predictable, the screening test should be evaluated depend-
ing on the clinical resources. For example, Poon et al. im-
proved the diagnosis of preeclampsia by the uterine artery 
pulsatility index as the most promising screening test [19, 
26] that accessibility testing is questionable. 
The strength of this study is the prospective investigation of 
pregnant women attending prenatal screening tests to detect 
a chromosomal abnormality and to examine fetal growth. 
Second, reducing the impact of confounding factors such as 
BMI by applying the women’s BMI <30. The limitation of 
this study is that the small population involved in the study.
CONCLUSION
The findings demonstrate that pregnancies with PAPP-A 
<10th percentile have an increased risk of adverse outcomes; 
however, the current studies considered it a poor predictor. 
Thus, PAPP-A combination with the other related predictors 
would improve the sensitivity and specificity of the screen-
ing. Second-trimester biomarkers to closely follow up the 
high-risk pregnancies for complications should be deter-
mined to prevent adverse complications. 
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